DexCom, Inc. (NASDAQ:DXCM) EVP Chad Patterson Sells 776 Shares

DexCom, Inc. (NASDAQ:DXCMGet Rating) EVP Chad Patterson sold 776 shares of the company’s stock in a transaction dated Monday, April 11th. The stock was sold at an average price of $498.75, for a total transaction of $387,030.00. Following the completion of the sale, the executive vice president now owns 14,452 shares in the company, valued at approximately $7,207,935. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Shares of DexCom stock traded up $8.37 on Wednesday, reaching $498.80. 495,683 shares of the company traded hands, compared to its average volume of 858,818. DexCom, Inc. has a 52 week low of $318.45 and a 52 week high of $659.45. The company has a 50 day moving average of $443.94 and a 200 day moving average of $507.97. The firm has a market capitalization of $48.58 billion, a PE ratio of 323.74, a PEG ratio of 8.50 and a beta of 0.94. The company has a debt-to-equity ratio of 0.76, a current ratio of 5.11 and a quick ratio of 4.62.

Shares of DexCom are set to split before the market opens on Friday, June 10th. The 4-1 split was announced on Friday, March 25th. The newly created shares will be payable to shareholders after the market closes on Thursday, June 9th.

DexCom (NASDAQ:DXCMGet Rating) last announced its quarterly earnings results on Thursday, February 10th. The medical device company reported $0.68 EPS for the quarter, missing the Zacks’ consensus estimate of $0.86 by ($0.18). The business had revenue of $698.20 million for the quarter, compared to analysts’ expectations of $698.66 million. DexCom had a net margin of 6.32% and a return on equity of 12.87%. The business’s quarterly revenue was up 22.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.91 earnings per share. As a group, analysts anticipate that DexCom, Inc. will post 3.39 earnings per share for the current year.

Several hedge funds have recently made changes to their positions in DXCM. Phoenix Holdings Ltd. purchased a new stake in shares of DexCom during the 3rd quarter valued at approximately $578,000. State of New Jersey Common Pension Fund D lifted its stake in shares of DexCom by 0.4% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 56,689 shares of the medical device company’s stock valued at $31,001,000 after buying an additional 245 shares in the last quarter. WINTON GROUP Ltd lifted its stake in shares of DexCom by 392.1% during the 3rd quarter. WINTON GROUP Ltd now owns 3,494 shares of the medical device company’s stock valued at $1,911,000 after buying an additional 2,784 shares in the last quarter. Compagnie Lombard Odier SCmA lifted its stake in shares of DexCom by 92.6% during the 3rd quarter. Compagnie Lombard Odier SCmA now owns 520 shares of the medical device company’s stock valued at $285,000 after buying an additional 250 shares in the last quarter. Finally, Emerald Advisers LLC lifted its stake in shares of DexCom by 30.3% during the 3rd quarter. Emerald Advisers LLC now owns 1,937 shares of the medical device company’s stock valued at $1,059,000 after buying an additional 450 shares in the last quarter. Institutional investors own 95.14% of the company’s stock.

A number of equities research analysts recently weighed in on the stock. Wells Fargo & Company upgraded shares of DexCom from an “equal weight” rating to an “overweight” rating and set a $575.00 target price on the stock in a report on Wednesday, January 19th. Guggenheim upgraded shares of DexCom from a “neutral” rating to a “buy” rating and set a $580.00 target price on the stock in a report on Friday, January 7th. Bank of America initiated coverage on shares of DexCom in a research report on Wednesday, March 2nd. They issued a “buy” rating for the company. Raymond James reduced their price objective on shares of DexCom from $618.00 to $538.00 and set an “outperform” rating for the company in a research report on Wednesday, January 19th. Finally, Citigroup reduced their price objective on shares of DexCom from $660.00 to $630.00 in a research report on Friday, February 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $565.33.

About DexCom (Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Featured Articles

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.